GlassScriptPhysician profile
Eric Chongze Ma
NPI 1205078862
$11,255.23
in general payments reported to CMS, 2019-2025
47 companies · $4,425 in 2025
The $4,425 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $234 · 2021: $89.88 · 2022: $513 · 2023: $2,327 · 2024: $2,783 · 2025: $4,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,732 · Honoraria: $1,650 · Travel and Lodging: $862 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,732.36 |
| Honoraria | $1,650.00 |
| Travel and Lodging | $862.48 |
| Education | $290.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $2,661.78 | 2024-2025 | Qinlock |
| Novartis Pharmaceuticals Corporation | $679.59 | 2020-2025 | |
| Abbvie INC. | $609.75 | 2019-2025 | |
| Janssen Biotech, INC. | $608.96 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $543.30 | 2019-2025 | Enhertu, Tagrisso, Calquence |
| Pharmacyclics LLC, An Abbvie Company | $404.84 | 2019-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $390.22 | 2019-2025 | |
| Celgene Corporation | $312.38 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $298.75 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Incyte Corporation | $287.09 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Jazz Pharmaceuticals INC. | $270.71 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $243.45 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $225.64 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Array Biopharma INC | $198.82 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Genzyme Corporation | $198.11 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $192.43 | 2019-2025 | Trodelvy |
| Eisai INC. | $187.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.23 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Lilly USA, LLC | $180.88 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $177.47 | 2023-2025 | Ojjaara, Jemperli, Blenrep |
| Daiichi Sankyo INC. | $174.19 | 2024-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $159.13 | 2019-2025 | |
| Mirati Therapeutics, INC. | $155.57 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $147.09 | 2023-2025 | Padcev, Xospata |
| Regeneron Healthcare Solutions, INC. | $142.93 | 2021-2025 | Libtayo |
| Seagen INC. | $142.12 | 2019-2023 | Tukysa |
| Genentech USA, INC. | $140.47 | 2019-2025 | Tecentriq, Avastin, Rozlytrek |
| Pharmaessentia USA Corporation | $138.22 | 2022-2025 | Besremi |
| Amgen INC. | $119.75 | 2022-2023 | Lumakras, Kyprolis |
| Ipsen Biopharmaceuticals, INC | $115.74 | 2019-2024 | Onivyde, Somatuline Depot |
| Coherus Oncology, INC. | $115.26 | 2022-2025 | Loqtorzi, Udenyca |
| Sobi, INC | $93.77 | 2023-2024 | |
| Stemline Therapeutics INC. | $92.97 | 2023-2025 | Orserdu |
| Adc Therapeutics America, INC. | $88.97 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $79.50 | 2023-2025 | |
| Puma Biotechnology, INC. | $77.14 | 2019-2024 | |
| Exelixis INC. | $66.34 | 2019-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $64.04 | 2023-2024 | Xpovio |
| Sumitomo Pharma America, INC. | $55.80 | 2024-2025 | Orgovyx |
| Emd Serono, INC. | $48.20 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $47.52 | 2023-2024 | Precisetumor, Myrisk |
| Amag Pharmaceuticals, INC. | $38.56 | 2019 | |
| Genmab U.S., INC. | $24.24 | 2024 | Tivdak |
| Aveo Pharmaceuticals, INC. | $21.60 | 2025 | |
| Kite Pharma, INC. | $19.79 | 2023 | |
| Agios Pharmaceuticals, INC. | $15.90 | 2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $15.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.